Pelthos Therapeutics (PTHS) Q4 2025: Zelsubmi Prescriptions Jump 129%, Expanding At-Home Pediatric Market
Pelthos Therapeutics’ Q4 marked a pivotal acceleration, as Zelsubmi prescriptions surged and channel access broadened, positioning the company for a multi-product pediatric dermatology platform. With strong initial uptake, disciplined SG&A control, and two FDA-approved acquisitions, Pelthos is now focused on deepening prescriber engagement and launching complementary products to capture outsized share in acute pediatric skin conditions.
Summary
- Prescription Velocity Surges: Zelsubmi’s rapid adoption signals strong product-market fit and payer acceptance.
- Commercial Leverage Grows: Expanded salesforce and PBM contracting enable broader access and operational scale.
- Pipeline Integration Ahead: Zepi and Zeglyze launches set up a multi-product revenue inflection by late 2026.
Business Overview
Pelthos Therapeutics is a specialty pharmaceutical company focused on pediatric and dermatological conditions. The company generates revenue primarily through sales of Zelsubmi, a novel at-home topical treatment for molluscum contagiosum (MC), and is building a portfolio with two additional FDA-approved products: Zepi for impetigo and Zeglyze for head lice. Pelthos leverages a dedicated salesforce targeting pediatricians and dermatologists, supported by commercial payor and Medicaid access strategies.
Performance Analysis
Q4 2025 marked a decisive inflection for Pelthos, with Zelsubmi prescriptions up 129% quarter-over-quarter to 6,232 units, driven by accelerating demand and improved market access. Net product revenue increased to $9.1 million, with nearly all Q4 sales derived from patient-dispensed units rather than channel stocking, underscoring authentic end-user traction. The number of unique prescribers also more than doubled, reaching 2,712, reflecting both breadth and depth of adoption within the pediatric and dermatology communities.
Gross-to-net (GTN) discounts rose to 28.7%, with management signaling a further increase to the mid-to-high 30% range as PBM contracts and Medicaid utilization expand. SG&A cash expenses declined 5% sequentially, despite the addition of 14 new sales reps and launch preparations for Zepi and Zeglyze, highlighting ongoing cost discipline. The quarterly net operating loss narrowed to $12.0 million, and adjusted EBITDA loss improved to $9.0 million, reflecting operating leverage as revenue scales.
- Prescription Acceleration: Zelsubmi’s 129% Rx growth was achieved despite Q4 being seasonally the weakest for MC claims.
- Channel Access Expansion: PBM contracting now covers 20 million lives, driving immediate improvements in patient access and prescription velocity.
- Operational Leverage: Incremental salesforce additions are already generating prescription volumes sufficient to cover their cost in new territories.
Pelthos enters 2026 with strengthened cash reserves, following $18 million in convertible notes and a $30 million term loan, supporting commercialization and launch investments for its growing portfolio.
Executive Commentary
"The rapid increase in prescriptions during our Q3 2025 launch paid for our initial sales force in slightly over two months, justifying the expansion of the sales force this quarter and our drive to cash flow."
Scott Plescia, Chief Executive Officer
"Net product revenue rose approximately 28% from $7.1 million in the third quarter of 2025, which was our first quarter of launch, to $9.1 million in the fourth quarter of 2025."
Frank Nuttall, Chief Financial Officer
Strategic Positioning
1. Zelsubmi as First-Line Standard
Zelsubmi’s unique at-home administration and strong payer coverage are driving its rapid adoption as the first-line therapy for MC, displacing older in-office treatments. Management’s focus is on maximizing prescriber breadth while deepening repeat usage among high-volume clinicians.
2. Multi-Product Pediatric Platform
The acquisitions of Zepi (impetigo) and Zeglyze (head lice) create a highly synergistic portfolio, with significant call overlap for the existing salesforce. Both products target acute, high-volume pediatric conditions and are expected to leverage Pelthos’ commercial infrastructure for efficient launches in late 2026 and mid-2027.
3. Access and Coverage Expansion
Pelthos has achieved 59% commercial and 99% Medicaid coverage for Zelsubmi, with contracting strategies that minimize access friction and support annual price increases. The company’s selective PBM contracting approach is designed to optimize gross-to-net economics while rapidly expanding patient reach.
4. Cost Discipline and Profitability Path
Despite launch investments, Pelthos demonstrated tight SG&A cost management, with cash expenses down sequentially and clear plans to keep incremental spend in check. Royalty obligations, salesforce expansion, and launch prep are expected to be offset by scaling revenues, supporting the company’s expectation to reach cash flow breakeven by year-end under the current plan.
5. Market Penetration Strategy
With nearly 4,000 unique prescribers through early March, the company is prioritizing both geographic breadth and deepening relationships with high-decile prescribers. Digital and DTC-style campaigns, such as YouTube commercials, are driving patient-driven demand and awareness, further accelerating market penetration.
Key Considerations
Pelthos’ Q4 performance demonstrates both commercial execution and strategic foresight, but the company’s next phase will test its ability to scale a multi-product platform efficiently.
Key Considerations:
- PBM and Medicaid Leverage: Rapid expansion in payer coverage is reducing access barriers and supporting prescription growth, but will continue to pressure GTN margins.
- Seasonality Impact: Prescription volumes are expected to peak in Q2 and Q3, with management planning for operational resilience during slower winter months.
- Salesforce ROI: Early data shows new reps are self-funding in weeks, validating the expansion model, though further scale will require sustained prescriber engagement.
- Pipeline Integration: Launches of Zepi and Zeglyze are staged to maximize commercial overlap, but require continued investment in manufacturing and market education.
Risks
Gross-to-net margin pressure will intensify as PBM and Medicaid utilization grows, potentially diluting revenue growth if not offset by volume gains. Seasonal swings in MC patient visits could drive quarterly volatility. Competitive responses from in-office treatments or new entrants remain a risk, though management emphasizes Zelsubmi’s unique at-home positioning. Execution risk around the successful launch and uptake of Zepi and Zeglyze is material, especially given limited historical precedent for multi-product leverage at this scale in pediatric dermatology.
Forward Outlook
For Q1 2026, Pelthos expects:
- GTN discounts to rise into the mid-to-high 30% range as PBM and Medicaid mix increases
- SG&A to increase modestly with full-quarter impact from new sales hires and launch prep for Zepi and Zeglyze
For full-year 2026, management has not provided explicit revenue or EPS guidance but:
- Expects continued strong prescription growth, particularly in spring and summer months
- Targets cash flow breakeven by year-end under the current business plan
Management highlighted:
- “We remain extremely confident about our revenue growth trajectory and believe that our current cash balance provides the runway to execute on our business plan.”
- “We anticipate the rest of the year, March through really October, being very strong as far as the increase in patients being seen.”
Takeaways
Pelthos’ commercial execution in Q4 validates Zelsubmi’s market fit and provides a blueprint for scaling a pediatric-focused specialty platform.
- Prescription Growth as Leading Indicator: The 129% sequential Rx increase, despite seasonal headwinds, signals robust demand and effective payer access strategies.
- Portfolio Synergy Opportunity: The staged launches of Zepi and Zeglyze will test Pelthos’ ability to drive operational leverage and cross-sell within its core customer base.
- Watch Margin Compression and Launch Execution: Investors should monitor gross-to-net trends and the pace of prescriber growth as leading indicators of sustainable profitability and market share gains.
Conclusion
Pelthos Therapeutics’ Q4 results demonstrate strong initial execution, with Zelsubmi’s rapid adoption and expanding payer access laying a foundation for a broader pediatric dermatology platform. The next 12 months will be critical as the company integrates new products, manages margin headwinds, and seeks to deliver on its cash flow and profitability roadmap.
Industry Read-Through
Pelthos’ success with Zelsubmi underscores a growing opportunity for at-home, parent-administered treatments in pediatric dermatology, particularly as payers and prescribers seek convenient, effective options for acute conditions. The company’s rapid PBM and Medicaid contracting demonstrates that novel therapies with clear patient benefit can achieve broad access, but also highlights the inevitability of gross-to-net margin compression as payer mix shifts. For specialty pharma peers, the Pelthos playbook—focused salesforce expansion, digital DTC engagement, and portfolio synergy—offers a replicable model for scaling in fragmented pediatric markets. Competitors in the MC, impetigo, and head lice segments should prepare for heightened commercial activity and evolving prescriber preferences favoring at-home solutions.